{"id":"W3038822856","doi":"10.1016/j.clml.2020.06.024","title":"Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Takeda Canada; Takeda Oncology; Amgen; Takeda Pharmaceuticals U.S.A.; British Microcirculation Society; Celgene","keywords":"Medicine; Bortezomib; Ixazomib; Internal medicine; Regimen; Multiple myeloma; Proteasome inhibitor; Clinical endpoint; Oncology; Surgery; Randomized controlled trial; Carfilzomib","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003080971,0.0002604453,0.0004169187,0.0001004809,0.0002097225,0.0007436062,0.0003256118,0.0002332893,0.002928816],"category_scores_gemma":[0.000309703,0.0001016867,0.0003564828,0.00009811128,0.0001895462,0.0003865305,0.0002440876,0.0008394847,0.0004047218],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003381322,"about_ca_system_score_gemma":0.0004116573,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005903111,"about_ca_topic_score_gemma":0.0008276235,"domain_scores_codex":[0.9998645,0.00002249035,0.000006497154,0.00002886763,0.00001912322,0.00005855072],"domain_scores_gemma":[0.9999102,0.00001905957,0.00001527142,0.00001560128,0.000008692477,0.00003115863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.05958666,0.005175421,0.01123207,0.00033309,0.0002919351,0.0003310851,0.000118632,0.003303743,0.6971797,0.001383007,0.002522296,0.2185424],"study_design_scores_gemma":[0.01009931,0.09490471,0.08405282,0.0001240485,0.001237327,0.002787535,0.0004297959,0.01800079,0.7521647,0.002094737,0.0340144,0.00008994507],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992822,0.003536583,0.00128558,0.000315943,0.0001476699,0.00003962338,0.0001236183,0.0001056846,0.001623201],"genre_scores_gemma":[0.9984475,0.000495146,0.0003521778,0.00006217369,0.00002274654,0.00001759439,0.0001198706,0.000009119574,0.0004736942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002928816,"threshold_uncertainty_score":0.009797871,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07255064007328885,"score_gpt":0.3545877338522112,"score_spread":0.2820370937789224,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}